Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Atezolizumab (aPDL1) in Combination With Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma (GBM)
Phase of Trial: Phase I/II
Latest Information Update: 29 Mar 2018
At a glance
- Drugs Atezolizumab (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Adverse reactions; Therapeutic Use
- 26 Mar 2018 Planned End Date changed from 1 Jun 2020 to 1 Jun 2021.
- 30 Jun 2017 Status changed from not yet recruiting to recruiting.
- 06 Jun 2017 New trial record